scholarly journals The correlation between age and sweat chloride levels in sweat tests

2017 ◽  
Vol 23 (4) ◽  
pp. 227-230 ◽  
Author(s):  
A.G. Faria ◽  
F.A.L. Marson ◽  
A.F. Ribeiro ◽  
J.D. Ribeiro
Keyword(s):  
Sweat Chloride ◽  
Sweat Tests

A NEW SCREENING TEST FOR CYSTIC FIBROSIS

PEDIATRICS ◽  
1965 ◽  
Vol 36 (5) ◽  
pp. 700-703
Author(s):  
Robert H. Gregg ◽  
Rudrick E. Boucher
Keyword(s):  
Cystic Fibrosis ◽  
Screening Test ◽  
Chloride Concentration ◽  
Test Method ◽  
Clinical Usefulness ◽  
Sweat Chloride ◽  
Sweat Tests

A device and method for analysis of sweat chloride concentration is presented. Analyses of tests done simultaneously on 85 subjects by two methods demonstrate clinical usefulness of the new test method. It is simple, inexpensive, and adaptable to use in the physician's office and in laboratories where sweat tests are done infrequently.

scholarly journals Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor Therapy in Three Subjects with the Cystic Fibrosis Genotype Phe508del/Unknown and Advanced Lung Disease

Genes ◽  
2021 ◽  
Vol 12 (8) ◽  
pp. 1178
Author(s):  
Vito Terlizzi ◽  
Carmela Colangelo ◽  
Giovanni Marsicovetere ◽  
Michele D’Andria ◽  
Michela Francalanci ◽  
...  
Keyword(s):  
Drug Response ◽  
Ex Vivo ◽  
Forced Expiratory Volume ◽  
Considerable Decrease ◽  
Six Minute Walk Test ◽  
Sweat Chloride ◽  
Access Program ◽  
Minute Walk

We evaluated the effectiveness and safety of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in three subjects carrying the Phe508del/unknown CFTR genotype. An ex vivo analysis on nasal epithelial cells (NEC) indicated a significant improvement of CFTR gating activity after the treatment. Three patients were enrolled in an ELX/TEZ/IVA managed-access program, including subjects with the highest percent predicted Forced Expiratory Volume in the 1st second (ppFEV1) < 40 in the preceding 3 months. Data were collected at baseline and after 8, 12 and 24 weeks of follow-up during treatment. All patients showed a considerable decrease of sweat chloride (i.e., meanly about 60 mmol/L as compared to baseline), relevant improvement of ppFEV1 (i.e., >8) and six-minute walk test, and an increase in body mass index after the first 8 weeks of treatment. No pulmonary exacerbations occurred during the 24 weeks of treatment and all domains of the CF Questionnaire-Revised improved. No safety concerns related to the treatment occurred. This study demonstrates the benefit from the ELX/TEZ/IVA treatment in patients with CF with the Phe508del and one unidentified CFTR variant. The preliminary ex vivo analysis of the drug response on NEC helps to predict the in vivo therapeutic endpoints.

Micro-flowcell conductometric sweat analysis for cystic fibrosis diagnosis

2000 ◽  
Vol 37 (3) ◽  
pp. 399-407 ◽  
Author(s):  
H Lewis Webster ◽  
Carmelo G Quirante
Keyword(s):  
Power Supply ◽  
Time Interval ◽  
Sweating Rate ◽  
Sensor Cell ◽  
Sweat Testing ◽  
Small Holders ◽  
Flow Through ◽  
To Receive ◽  
Conductivity Cell ◽  
Sweat Tests

This paper describes a device specifically designed to facilitate neonatal sweat testing. The components are sized appropriately for attachment to the limbs of newborns. Iontophoretic electrodes, with pilocarpine gel inserts, are latched into small holders attached by straps to the limb. The holder at the anodic site remains in place to receive and align the sensor cell, which uses a conical collecting surface to channel the sweat directly and anaerobically from the sweat ducts to the continuous flow-through conductivity cell within its body. A crib-side analysis unit incorporates an iontophoretic power supply and displays a continuous readout of sweat electrical conductivity. The average conductivity during a specific time interval and the initial sweating rate are automatically displayed. The method, which simplifies sweat tests, is currently being assessed in three neonatal clinical trials to test its ability to reduce test failures in the newborn due to insufficient sweat.

Observations on skin resistance to electricity and sweat chloride content

1962 ◽  
Vol 60 (5) ◽  
pp. 716-720 ◽  
Author(s):  
Randolph Batson ◽  
William C. Young ◽  
Frank M. Shepard
Keyword(s):  
Skin Resistance ◽  
Chloride Content ◽  
Sweat Chloride

scholarly journals Disposition of MDMA and Metabolites in Human Sweat Following Controlled MDMA Administration

2009 ◽  
Vol 55 (3) ◽  
pp. 454-462 ◽  
Author(s):  
Allan J Barnes ◽  
Bruno S De Martinis ◽  
David A Gorelick ◽  
Robert S Goodwin ◽  
Erin A Kolbrich ◽  
...  
Keyword(s):  
Solid Phase ◽  
Random Order ◽  
Research Unit ◽  
Sweat Test ◽  
Test Results ◽  
Double Blind ◽  
Scientific Database ◽  
Sweat Testing ◽  
Clinical Research Unit ◽  
Sweat Tests

Abstract Background: Understanding the excretion of 3,4-methylenedioxymethamphetamine (MDMA) and metabolites in sweat is vital for interpretation of sweat tests in drug treatment, criminal justice, and workplace programs. Methods: Placebo, low (1.0 mg/kg), and high (1.6 mg/kg) doses of oral MDMA were given double-blind in random order to healthy volunteers (n = 15) with histories of MDMA use. Participants resided on the closed clinical research unit for up to 7 days after each dose. Volunteers wore PharmChek® sweat patches (n = 640) before, during, and after controlled dosing. Patches were analyzed by solid phase extraction and GC-MS for MDMA, methylenedioxyamphetamine (MDA), 4-hydroxy-3-methoxyamphetamine (HMA), and 4-hydroxy-3-methoxymethamphetamine (HMMA). Limits of quantification (LOQ) were 2.5 ng/patch for MDMA and 5 ng/patch for HMA, HMMA, and MDA. Results: MDMA was the primary analyte detected in 382 patches (59.7%), with concentrations up to 3007 ng/patch. MDA was detected in 188 patches (29.4%) at &lt;172 ng/patch, whereas no HMMA or HMA was detected; 224 patches (35.0%) and 60 patches (9.4%) were positive for MDMA and MDA, respectively, at the 25-ng/patch threshold proposed by the Substance Abuse and Mental Health Services Administration. Conclusions: Sweat testing was shown to be an effective and reliable method for monitoring MDMA use in this controlled MDMA administration study. However, variability in sweat excretion suggests that results should be interpreted qualitatively rather than quantitatively. These data provide a scientific database for interpretation of MDMA sweat test results.

Defining Asthma in the Preschool-Aged Child

PEDIATRICS ◽  
2002 ◽  
Vol 109 (Supplement_E1) ◽  
pp. 357-361
Author(s):  
Robert C. Strunk
Keyword(s):  
Chart Review ◽  
Skin Testing ◽  
Definitive Diagnosis ◽  
Pulmonary Medicine ◽  
Specific Test ◽  
Sweat Chloride ◽  
Preschool Aged Child ◽  
Aged Child ◽  
Allergy Skin Testing ◽  
Rule Out

A physician faces many challenges in making a definitive diagnosis of asthma in young children. Although there are clinical and historical features consistent with asthma, identical features are present in many other diseases. Furthermore, there is no specific test for asthma. Other diseases must always be ruled out before a definitive diagnosis of asthma is made. Determining whether cough or wheeze is the primary symptom is important because asthma is primarily a wheezing disease. Sweat chloride testing, chest radiography, and allergy skin testing should be performed in children with persistent wheezing to rule out other causes and help support a diagnosis of asthma. Allergy skin testing provides particularly useful information for making a diagnosis of asthma in the preschool-aged child. A chart review of patients presenting consecutively to the Division of Allergy and Pulmonary Medicine provides insight and information on an approach to make an asthma diagnosis for this population.

Sign in / Sign up

Export Citation Format

Share Document